维亚臻生物技术（上海）有限公司

维亚臻成立于2022年，并与*的小核酸药物企业Arrowhead Pharmaceuticals (NASDAQ: ARWR)建立战略合作关系。目前公司产品管线拥有三款处于临床研发阶段、针对心血管及代谢领域的小核酸(siRNA)药物。此外，公司拥有自主研发能力，将在肝内及肝外递送技术、以及更广阔的治疗领域进行探索。
公司现有管线在同类竞品中处于领先位置，其靶点具有明确的基因组学及生物学证据支持，使用Arrowhead已经验证的递送及化学修饰技术平台。公司采用中美协同的临床开发及注册策略，有助于加速产品上市。
公司的内部研发能力将进一步丰富包括心血管及代谢领域在内的临床研发管线，实现公司的长期可持续发展，同时通过内外部资源形成从研发、生产至销售的全产业链布局。

Visirna was founded in 2022 in a strategic partnership with Arrowhead Pharmaceuticals (NASDAQ: ARWR). Based in China, with a global vision, Visirna aims to be a leading player in the research development of oligonucleotide therapeutics. We currently have three first-in- late clinical-stage siRNA candidates licensed from Arrowhead Pharmaceuticals fthe treatment of cardiovascular metabolic diseases.
We are rapidly advancing our clinical pipelines in an array of trials. Currently we have one ongoing Phase 3 registration trial in FCS in China, will soon join multiple MRCT trials fcardiovascular diseases. At the same time, we are also conducting a phase 2 PoC (proof of concept) trial in NASH.
Visirna is setting up a 1500 sqm R&D lab in Suzhou BioBAY to strengthen our existing clinical portfolio fcardiovascular metabolic diseases. Our goal is to develop a comprehensive treatment repertoire that can effectively address the complex nature of these diseases provide better outcomes fpatients.